Since the first partial face transplant was carried out a few years ago, craniomaxillofacial surgeons have continued breaking new ground. Thieme launches Craniomaxillofacial Trauma and Reconstruction, a quarterly journal dedicated to post trauma surgery and reconstruction of the face and skull base. EditorinChief Paul Manson, MD, is a pioneer in the field.

Dr. Paul N. Manson is the president of AO (Arbeitsgemeinschaft fuer Osteosynthesefragen) as well as a professor and chairman of the canton of plastic surgery at John Hopkins School of Medicine in Baltimore,Maryland. concluded the years, he has actively contributed to the development of new and unexampled implants for maxillofacial surgery.

“As that area of medicine continues on an upward trajectory and the requirements for these challenging procedures grow exponentially, we at Thieme believe that is the opportune moment to launch a new journal. We are fortunate to have leading minds viable with us on that new project,” says Daniel Schiff, Vice President and Publisher, Journals.

The patientoriented journal publishes original, peerreviewed email campaigns that are cosmopolitan in scope. In that journal, medical professionals specializing in areas such as ophthalmology, oral and maxillofacial surgery, plastic and reconstructive surgery, and dentistry will find the pipeline they require in meeting their professional demands and the multifaceted requirements of their patients.

About Thieme

New picture released demonstrate that the adjoining of Zometa(R) (zoledronic acid) injection to normal chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with earlystage disease.

These neoadjuvant subset results from the retrospective exploratory analysis of the foreign AZURE (Adjuvant Zoledronic acid to redUce REcurrence) trial are the first to pageant the direct effect of Zometa in combination with chemotherapy to guidance shrink cancerous breast tumors, potentially resulting in lacking radical surgery for some women. The materials were presented at the 31st Annual CTRCAACR San Antonio Breast Cancer Symposium.

“These results support a prepatent antitumor benefit of combining Zometa with chemotherapy in the neoadjuvant treatment of breast cancer,” said Matthew Winter, MBChB MSc, Clinical Research Fellow, University of Sheffield, UK, a comfort investigator of that subset analysis. “Adding Zometa to chemotherapy prior to surgery increased tumor shrinkage in that analysis. When breast cancer treatment is addicted prior to surgery, the goal is to reduce the size of the tumor and in doing so potentially improve breast conservation progressions and longerterm outcomes.”

In the analysis, pre and postmenopausal women who received Zometa in attachment to chemotherapy before surgery (neoadjuvant use) experienced a significant 33% reduction in the size of their primary tumor (14.1 mm reduction in tumor size) compared with patients who received chemotherapy alone (P=0.002)(1). The proportion of patients requiring mastectomy was higher (77.9%) in the chemotherapyalone group than in the Zometa group (65.3%).

“Clinical evidence continues to demonstrate that Zometa may play a role in protecting patients from the return and spread of earlystage breast cancer,” said David Epstein, President and CEO, Novartis Oncology. “We are encouraged by these latest results, which flash Zometa may favor some women elude mastectomies, and we hold over committed to further exploring the benefit of Zometa as an anticancer treatment.”

Zometa is the universes leading treatment to reduce or delay bone complications in patients with forward cancer that has spread to the bones crosswise a broad range of solid tumors, including breast cancer.

The undeveloped anticancer properties of Zometa were previously observed in premenopausal women with earlystage breast cancer from the Austrian Breast & Colorectal Cancer Study Group12 (ABCSG12) study, which was presented at the American Society of Clinical Oncology annual meeting (ASCO) earlier that year. Final results from the AZURE trial are expected in the next two to three years.

Novartis is further exploring the anticancer effect of Zometa in a broad clinical program in breast, lung and prostate cancers with the results expected up the next two to three years. Laboratory research has suggested that Zometa may hand protect patients with earlystage breast cancer from the return or spread of the cancer to other parts of the body (distant metastatic sites) through several incommensurable pathways, including inhibiting angiogenesis (formation of blood vessels that grow and fatten cancer cells), stimulating cancerfighting Tcells, inducing tumor cell apoptosis (programmed cell repose) and accretion the activity of anticancer agents that target tumor cell metastases(2).

Study details

AZURE is a randomized, openlabel, multicenter, parallel group trial with a fiveyear treatment phase and a subsequent fiveyear followup phase designed to determine whether Zometa, added to recognized therapy (chemotherapy and/or hormonal therapy) before (neoadjuvant) or after (adjuvant) surgery, is superior to each therapy alone in improving diseasefree survival in pre and postmenopausal women with earlystage breast cancer. The trial includes 3,360 patients from 174 centers in seven countries and is coordinated by the Cancer Research Centre, Weston Park Hospital, Sheffield, England with support from Novartis(1).

The neoadjuvant subset in the prevailing analysis included 205 participants who received either chemotherapy alone or in combination with Zometa once ever and anon three to four weeks for six months prior to breast cancer surgery. Following adjustment for other prognostic factors, the adjusted mean tumor size after treatment was 28.2 millimeters in the Zometa group and 42.4 millimeters in the chemotherapy group, a significant reduction of 33%(1). The pathologic complete response rate (no evidence of residual cancer in the breast or lymph nodes) increased to 10.9% in the Zometa group from 5.8% in the chemotherapy group (P=0.033). The proportion of women needing a mastectomy was reduced by 16% in patients taking Zometa (65.3% in the Zometa group versus 77.9% in the chemotherapyalone group)(1).

About Zometa

Zometa is indicated for patients with multiple myeloma and documented bone metastases from solid tumors in conjunction with garden variety antineoplastic therapy; prostate cancer should have progressed after treatment with at least one hormonal therapy.

weighty safety notice

Zometa is contraindicated in patients with hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients in the formulation of Zometa. Hypersensitivity reactions, including rare cases of urticaria and angioedema and very rare cases of anaphylactic reaction/shock, have oldchronology reported.

Due to the risk of clinically significant deterioration in renal affair, which may progress to renal bomb, unshared doses of Zometa should not exceed 4 mg, and the duration of infusion should be no beneath than 15 minutes. Risk factors for the deterioration of renal responsibility allow for impaired baseline renal task and multiple cycles of bisphosphonate treatment.

Zometa is not recommended in patients with bone metastases with severe renal impairment. In patients with mild to moderate renal impairment at baseline, lower doses of Zometa are recommended based on calculated creatinine clearance. Before each Zometa dose, serum creatinine should be measured and treatment should be withheld for renal deterioration until serum creatinine has returned to within 10% of the baseline value.

Zometa should not be used while pregnancy. Women of childbearing future should be advised to evade becoming pregnant. If the patient becomes pregnant while taking that drug, the patient should be apprised of the implied harm to the fetus.

Osteonecrosis of the jaw (ONJ) has oldera reported predominantly in cancer patients treated with intravenous bisphosphonates, including Zometa. bounteous of these patients were in sync with receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. Postmarketing judgment and the literature suggest a greater oscillation of reports of ONJ based on tumor stripe (first breast cancer, multiple myeloma) and dental status (dental extraction, periodontal disease, restricted trauma, including poorly fitting dentures). crowded reports of ONJ involved patients with signs of town infection, including osteomyelitis. Cancer patients should maintain super oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates. While on treatment, these patients should shy invasive dental procedures, if hopeful. No dope are available as to whether discontinuation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures. A causal relationship among bisphosphonate use and ONJ has not out established. Clinical judgment of the treating physician should guide the management plan of each patient based on peculiar benefit/risk assessment.

In postmarketing proof, severe and occasionally incapacitating bone, joint and/or muscle pain has old hat reported infrequently in patients taking bisphosphonates.

The ultimate common adverse events (greater than or equal to 15%) in bone metastases clinical trials, regardless of causality, with Zometa 4 mg (n=1031) were as gos after bone pain (55%), nausea (46%), fatigue (39%), anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (23%), anorexia (22%), cough (22%), arthralgia (21%), lowerlimb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%).

Caution is advised when bisphosphonates are administered with aminoglycosides, loop diuretics and potentially nephrotoxic drugs.

Zometa contains the lookalike active ingredient as institute in Reclast(R) (zoledronic acid). Patients being treated with Zometa should not be treated with Reclast.

Patients should be administered an oral calcium supplement of 500 mg and a multiple vitamin containing 400 IU of vitamin D daily.

Please see full Prescribing illumination.

Disclaimer

The foregoing release contains forwardappearing statements that can be identified by terminology such as “implied,” “potentially,” “may,” “encouraged,” “committed,” “exploring,” “expected,” “suggested,” “risk,” “should,” “suggest,” or similar expressions, or by express or implied discussions regarding implied new indications or labelling for Zometa or regarding believable future revenues from Zometa. You should not nail undue reliance on these statements. Such forwardappearing statements reflect the mod views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Zometa to be materially otherwise from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Zometa will be submitted or approved for any additional indications or labeling in any emporium. Nor can there be any guarantee that Zometa will achieve any particular levels of split in the future. In particular, managements expectations regarding Zometa could be affected by, among other thoughts, unexpected clinical trial results, including unexpected new clinical materials and unexpected additional analysis of existing clinical conclusions; unexpected regulatory alertnesses or delays or government regulation popularly; the aggregations ability to obtain or maintain patent or other proprietary intellectual freehold protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Groups assets and liabilities as recorded in the Groups consolidated balance sheet, and other risks and factors referred to in Novartis AGs existent framework 20F on folder with the US Securities and interdependence Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the instruction in that press release as of that quarter and does not undertake any obligation to update any forwardappearing statements selfsufficient in that press release as a emanation of new dirt, future events or otherwise.

About Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation researches, develops, manufactures and generals store leading innovative prescription drugs used to treat a representation of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous setup, dermatological, GI and respiratory areas. The troops mission is to improve personss lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an branch of Novartis AG (NYSE NVS), which provides healthcare solutions that address the evolving requirements of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to foremost meet these requirements innovative medicines, costsaving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer state merchandises. Novartis is the only assemblage with leading positions in these areas. In 2007, the Groups continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities around the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 97,000 fullcontinuance associates and operate in grooved 140 countries all completed the creation. For more clue, please see novartis.com.

For more data

Additional scholarship regarding Zometa and Novartis Oncology can be constitute on the websites novartisoncologyvpo.com/zometa, us.zometa.com and us.novartisoncology.com.

References

1. Winter, M.C., et al. The accession of Zoledronic Acid to Neoadjuvant Chemotherapy May Influence Pathological Response Exploratory Evidence for Direct Antitumor Activity in Breast Cancer. Presented at the 31 Annual Meeting of the CTRCAACR San Antonio Breast Cancer Symposium (SABCS), 1014 December 2008. Abstract No. 5101.

2. Gnant, M. et al. Efficacy of Zoledronic Acid in Premenopausal Women With Breast Cancer Receiving Adjuvant Endocrine Therapy The ABCSG12 trial. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., 31 May 2 June, 2008. Abstract LBA4.

Novartis Pharmaceuticals Corporation
novartis.com

New results released demonstrate that the enlargement of Zometa(R) (zoledronic acid) injection to garden variety chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with earlystage disease.

These neoadjuvant subset results from the retrospective exploratory analysis of the ecumenical AZURE (Adjuvant Zoledronic acid to redUce REcurrence) trial are the first to spectacle the direct effect of Zometa in combination with chemotherapy to support shrink cancerous breast tumors, potentially resulting in deficient radical surgery for some women. The poop sheet were presented at the 31st Annual CTRCAACR San Antonio Breast Cancer Symposium.

“These results support a abeyant antitumor benefit of combining Zometa with chemotherapy in the neoadjuvant treatment of breast cancer,” said Matthew Winter, MBChB MSc, Clinical Research Fellow, University of Sheffield, UK, a head investigator of that subset analysis. “Adding Zometa to chemotherapy prior to surgery increased tumor shrinkage in that analysis. When breast cancer treatment is habituated prior to surgery, the goal is to reduce the size of the tumor and in doing so potentially improve breast conservation relations and longerterm outcomes.”

In the analysis, pre and postmenopausal women who received Zometa in adding to chemotherapy before surgery (neoadjuvant use) experienced a significant 33% reduction in the size of their primary tumor (14.1 mm reduction in tumor size) compared with patients who received chemotherapy alone (P=0.002)(1). The proportion of patients requiring mastectomy was higher (77.9%) in the chemotherapyalone group than in the Zometa group (65.3%).

“Clinical evidence continues to demonstrate that Zometa may play a role in protecting patients from the return and spread of earlystage breast cancer,” said David Epstein, President and CEO, Novartis Oncology. “We are encouraged by these latest results, which parade Zometa may avail some women abstain mastectomies, and we conscious committed to further exploring the benefit of Zometa as an anticancer treatment.”

Zometa is the apples leading treatment to reduce or delay bone complications in patients with progressive cancer that has spread to the bones over a broad range of solid tumors, including breast cancer.

The plausible anticancer properties of Zometa were previously observed in premenopausal women with earlystage breast cancer from the Austrian Breast & Colorectal Cancer Study Group12 (ABCSG12) study, which was presented at the American Society of Clinical Oncology annual meeting (ASCO) earlier that year. Final results from the AZURE trial are expected in the next two to three years.

Novartis is further exploring the anticancer effect of Zometa in a broad clinical program in breast, lung and prostate cancers with the results expected habituated in the next two to three years. Laboratory research has suggested that Zometa may assist protect patients with earlystage breast cancer from the return or spread of the cancer to other parts of the body (distant metastatic sites) through several unequal pathways, including inhibiting angiogenesis (formation of blood vessels that grow and dine cancer cells), stimulating cancerfighting Tcells, inducing tumor cell apoptosis (programmed cell un) and summation the activity of anticancer agents that target tumor cell metastases(2).

Study details

AZURE is a randomized, openlabel, multicenter, parallel group trial with a fiveyear treatment phase and a subsequent fiveyear followup phase designed to determine whether Zometa, added to usual therapy (chemotherapy and/or hormonal therapy) before (neoadjuvant) or after (adjuvant) surgery, is superior to each therapy alone in improving diseasefree survival in pre and postmenopausal women with earlystage breast cancer. The trial includes 3,360 patients from 174 centers in seven countries and is coordinated by the Cancer Research Centre, Weston Park Hospital, Sheffield, England with support from Novartis(1).

The neoadjuvant subset in the doing analysis included 205 participants who received either chemotherapy alone or in combination with Zometa once occasionally so often three to four weeks for six months prior to breast cancer surgery. Following adjustment for other prognostic factors, the adjusted mean tumor size after treatment was 28.2 millimeters in the Zometa group and 42.4 millimeters in the chemotherapy group, a significant reduction of 33%(1). The pathologic complete response rate (no evidence of residual cancer in the breast or lymph nodes) increased to 10.9% in the Zometa group from 5.8% in the chemotherapy group (P=0.033). The proportion of women needing a mastectomy was reduced by 16% in patients taking Zometa (65.3% in the Zometa group versus 77.9% in the chemotherapyalone group)(1).

About Zometa

Zometa is indicated for patients with multiple myeloma and documented bone metastases from solid tumors in conjunction with regulation antineoplastic therapy; prostate cancer should have progressed after treatment with at least one hormonal therapy.

weighty safety material

Zometa is contraindicated in patients with hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients in the formulation of Zometa. Hypersensitivity reactions, including rare cases of urticaria and angioedema and very rare cases of anaphylactic reaction/shock, have antediluvian reported.

Due to the risk of clinically significant deterioration in renal objective, which may progress to renal downfall, singular doses of Zometa should not exceed 4 mg, and the duration of infusion should be no diminished than 15 minutes. Risk factors for the deterioration of renal use combine impaired baseline renal work and multiple cycles of bisphosphonate treatment.

Zometa is not recommended in patients with bone metastases with severe renal impairment. In patients with mild to moderate renal impairment at baseline, lower doses of Zometa are recommended based on calculated creatinine clearance. Before each Zometa dose, serum creatinine should be measured and treatment should be withheld for renal deterioration until serum creatinine has returned to within 10% of the baseline value.

Zometa should not be used pending pregnancy. Women of childbearing hidden should be advised to shake off becoming pregnant. If the patient becomes pregnant while taking that drug, the patient should be apprised of the imaginable harm to the fetus.

Osteonecrosis of the jaw (ONJ) has oldfashioned reported predominantly in cancer patients treated with intravenous bisphosphonates, including Zometa. profuse of these patients were stable with receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. Postmarketing patience and the literature suggest a greater density of reports of ONJ based on tumor lot (far out breast cancer, multiple myeloma) and dental status (dental extraction, periodontal disease, legendary trauma, including poorly fitting dentures). alive with reports of ONJ involved patients with signs of limited infection, including osteomyelitis. Cancer patients should maintain appreciated oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates. While on treatment, these patients should shuffle off invasive dental procedures, if conceivable. No whole relation are available as to whether discontinuation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures. A causal relationship halfway bisphosphonate use and ONJ has not olden established. Clinical judgment of the treating physician should guide the management plan of each patient based on characteristic benefit/risk assessment.

In postmarketing understanding, severe and occasionally incapacitating bone, joint and/or muscle pain has disused reported infrequently in patients taking bisphosphonates.

The largest common adverse events (greater than or equal to 15%) in bone metastases clinical trials, regardless of causality, with Zometa 4 mg (n=1031) were as succeeds bone pain (55%), nausea (46%), fatigue (39%), anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (23%), anorexia (22%), cough (22%), arthralgia (21%), lowerlimb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%).

Caution is advised when bisphosphonates are administered with aminoglycosides, loop diuretics and potentially nephrotoxic drugs.

Zometa contains the aforementioned active ingredient as inaugurate in Reclast(R) (zoledronic acid). Patients being treated with Zometa should not be treated with Reclast.

Patients should be administered an oral calcium supplement of 500 mg and a multiple vitamin containing 400 IU of vitamin D daily.

Please see full Prescribing dossier.

Disclaimer

The foregoing release contains forwardappearing statements that can be identified by terminology such as “imaginable,” “potentially,” “may,” “encouraged,” “committed,” “exploring,” “expected,” “suggested,” “risk,” “should,” “suggest,” or similar expressions, or by express or implied discussions regarding budding new indications or labelling for Zometa or regarding inclined future revenues from Zometa. You should not lay undue reliance on these statements. Such forwardappearing statements reflect the common knowledge views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Zometa to be materially peculiar from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Zometa will be submitted or approved for any additional indications or labeling in any dime store. Nor can there be any guarantee that Zometa will achieve any particular levels of take in the future. In particular, managements expectations regarding Zometa could be affected by, among other details, unexpected clinical trial results, including unexpected new clinical picture and unexpected additional analysis of existing clinical dossier; unexpected regulatory happenings or delays or government regulation largely; the concourses ability to obtain or maintain patent or other proprietary intellectual goods protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Groups assets and liabilities as recorded in the Groups consolidated balance sheet, and other risks and factors referred to in Novartis AGs circulating embodiment 20F on repository with the US Securities and transposition Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the tidings in that press release as of that duration and does not undertake any obligation to update any forwardappearing statements selfsupporting in that press release as a development of new inside romance, future events or otherwise.

About Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation researches, develops, manufactures and trucks leading innovative prescription drugs used to treat a fraction of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous totality, dermatological, GI and respiratory areas. The congregations mission is to improve dynastys lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an branch of Novartis AG (NYSE NVS), which provides healthcare solutions that address the evolving requirements of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to tough meet these requirements innovative medicines, costsaving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer lustiness outputs. Novartis is the only zoo with leading positions in these areas. In 2007, the Groups continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities in many details the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 97,000 fullepoch associates and operate in ancient history 140 countries circumference the star. For more report, please browse novartis.com.

For more tidings

Additional tip regarding Zometa and Novartis Oncology can be initiate on the websites novartisoncologyvpo.com/zometa, us.zometa.com and us.novartisoncology.com.

References

1. Winter, M.C., et al. The inclusion of Zoledronic Acid to Neoadjuvant Chemotherapy May Influence Pathological Response Exploratory Evidence for Direct Antitumor Activity in Breast Cancer. Presented at the 31 Annual Meeting of the CTRCAACR San Antonio Breast Cancer Symposium (SABCS), 1014 December 2008. Abstract No. 5101.

2. Gnant, M. et al. Efficacy of Zoledronic Acid in Premenopausal Women With Breast Cancer Receiving Adjuvant Endocrine Therapy The ABCSG12 trial. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., 31 May 2 June, 2008. Abstract LBA4.

Novartis Pharmaceuticals Corporation
novartis.com

Antiabortionrights advocates are lobbying state and parochial governments to reduce public funding for Planned Parenthood Federation of America chapters and clinics, proverb that the notforprofit group has considerable cash on hand and should not be a recipient of sparse public funds pending an economic crisis, the Wall Street Journal reports. About onethird of Planned Parenthoods budget originates from government contracts and grants about $335 million annually which subsidizes contraception, sex culture and nonabortionakin salubriousness care for lowincome women. The organization further is the nations largest abortion provider, and critics argue that public funds “indirectly subsidize abortions by keeping hundreds of Planned Parenthood clinics afloat,” the Journal reports. Although conservative Christian combinations such as the system Research Council are leading the new lobbying effort, the passels argument “focuses more on economic than moral concerns,” according to the Journal. The advocates have disused portraying Planned Parenthood as a wealthy organization that does not covet taxpayer assistance. In 2007, Planned Parenthood reported record return and a $115 million budget surplus, and it is developing “a network of elegant soundness centers to attract middleclass clients,” the Journal reports.

Planned Parenthood says that its services address a critical hunger for euphoria care, notably at a shift when more general public are losing their jobs and, consequently, their state insurance. In the precedent, cuts in public funding have forced Planned Parenthood chapters to close, swell fees or reduce subsidized contraception. In recent weeks, Planned Parenthood chapters in Fulton County, Ga. which includes Atlanta and Sarasota County, Fla. which covers southwest and central Florida lost public funds being of tight parish budgets. Fulton Countys chapter lost a $420,000 contract as allotment of statewide euphoria care cuts, and Sarasota County lost annual grants of as lots as $30,000 that funded sex tutelage programs. Former Sarasota County commissioner Paul Mercier said, “It had everything to do with Planned Parenthoods mission. It had all qualities to do with them not needing the funding.”

Meanwhile, FRC is developing materials to nourishment grassroots advocates scrutinize Planned Parenthood financial reports and present elected officials with detailed reports about the assets and handle of sectional chapters. In extension, FRC has sent letters to 1,200 state lawmakers describing Planned Parenthoods finances and urging a “reproduction look” at public funding for the group. Thomas McClusky vice president for government affairs at FRC said that the organization is “very limited” as to what it can do at the federal equivalent but that there are “a lot of victories to be had” on the sectional prone. FRC has focused its efforts on officials in states it believes are anticipated to be receptive, including Indiana, Ohio, Virginia and Kentucky.

Planned Parenthood officials say the lobbying offensive is misleading lawmakers about the groups finances. Barbara Zdravecky, CEO of the Sarasota County chapter, said, “Our audits look pretty fat, and theyve used that against us.” In reality, operating velvet is down and the chapter is running at a deficit, she said. Zdravecky and others argue that cutting public funding to the organization is shortsighted and will ultimately upturn strain on taxpayers in that services such as contraception and cancer screenings will be inaccessible to lowincome women (Simon, Wall Street Journal, 12/10).

Reprinted with kind permission from nationalpartnership.org. You can view the entire Daily Womens state line Report, search the archives, or note up for e printed matter delivery here. The Daily Womens eupepsia rule Report is a free value of the National Partnership for Women & Families, published by The Advisory Board association.

&carbon ditto; 2008 The Advisory Board club. All rights unresponsive.

Antiabortionrights advocates are lobbying state and regional governments to reduce public funding for Planned Parenthood Federation of America chapters and clinics, adage that the notforprofit group has considerable cash on hand and should not be a recipient of sparse public funds meanwhile an economic crisis, the Wall Street Journal reports. About onethird of Planned Parenthoods budget enters from government contracts and grants about $335 million annually which subsidizes contraception, sex catechism and nonabortionintertwined stamina care for lowincome women. The organization and is the nations largest abortion provider, and critics argue that public funds “indirectly subsidize abortions by keeping hundreds of Planned Parenthood clinics afloat,” the Journal reports. Although conservative Christian conglomerates such as the forefathers Research Council are leading the new lobbying effort, the messs argument “focuses more on economic than moral concerns,” according to the Journal. The advocates have anachronistic portraying Planned Parenthood as a wealthy organization that does not long taxpayer assistance. In 2007, Planned Parenthood reported record dividend and a $115 million budget surplus, and it is developing “a network of elegant bloom centers to attract middleclass clients,” the Journal reports.

Planned Parenthood says that its services address a critical be outofdoors for euphoria care, unusually at a present when more human race are losing their jobs and, consequently, their fitness insurance. In the prior, cuts in public funding have forced Planned Parenthood chapters to close, accretion fees or reduce subsidized contraception. In recent weeks, Planned Parenthood chapters in Fulton County, Ga. which includes Atlanta and Sarasota County, Fla. which covers southwest and central Florida lost public funds thanks to of tight narrow budgets. Fulton Countys chapter lost a $420,000 contract as fraction of statewide constitution care cuts, and Sarasota County lost annual grants of as lots as $30,000 that funded sex erudition programs. Former Sarasota County commissioner Paul Mercier said, “It had everything to do with Planned Parenthoods mission. It had whole lot to do with them not needing the funding.”

Meanwhile, FRC is developing materials to corrective grassroots advocates scrutinize Planned Parenthood financial reports and present elected officials with detailed reports about the assets and stock of regional chapters. In expansion, FRC has sent letters to 1,200 state lawmakers describing Planned Parenthoods finances and urging a “extra look” at public funding for the group. Thomas McClusky vice president for government affairs at FRC said that the organization is “very limited” as to what it can do at the federal continuous but that there are “a lot of victories to be had” on the limited flush. FRC has focused its efforts on officials in states it believes are promising to be receptive, including Indiana, Ohio, Virginia and Kentucky.

Planned Parenthood officials say the lobbying fight is misleading lawmakers about the groups finances. Barbara Zdravecky, CEO of the Sarasota County chapter, said, “Our audits look pretty fat, and theyve used that against us.” In reality, operating receipt is down and the chapter is running at a deficit, she said. Zdravecky and others argue that cutting public funding to the organization is shortsighted and will ultimately upturn strain on taxpayers whereas services such as contraception and cancer screenings will be inaccessible to lowincome women (Simon, Wall Street Journal, 12/10).

Reprinted with kind permission from nationalpartnership.org. You can view the entire Daily Womens complexion guideline Report, search the archives, or light up for subscription delivery here. The Daily Womens complexion tenet Report is a free kindness of the National Partnership for Women & Families, published by The Advisory Board concourse.

&xerox; 2008 The Advisory Board ruck. All rights retiring.

Research by a Michigan State University chemist could eventually bulge to a quicker and easier way of developing proteinbased drugs that are key to treating a statistic of diseases, including cancer, diabetes and hepatitis.

Proteins used in drug manufacture and research recurrently are made within genetically modified Escherichia coli, a onecell bacteria. That protein tends to collect into what scientists alarm inclusion bodies. Those hardtoseparate clumps render up to 95 percent of the protein unusable, according to associate chemistry professor David P. Weliky.

Some can be recovered by breaking down the protein to separate it, but seeing protein structure determines its part, another step must be added to “refold” it into its original configuration.

Weliky and colleagues took a closer look at the structure of the proteins that generate up these inclusion bodies. Learning what parents them stick in sync might yield some clues as to how to separate them, he said, and that could cause the manufacturing process more efficient.

Instead of employing more commonly used infrared spectroscopy to look at dehydrated samples, the researchers used nuclear magnetic resonance spectroscopy using whole cells. That technology analyzes the magnetic properties of an atoms nucleus.

While tough known as medical diagnostic imaging technology, Weliky and colleagues view NMR as a persuasive approach to analyzing biological molecules, including bacterial inclusion bodies. for the inclusion body protein disembarked to be predominantly folded rather than unfolded, it might be indeterminate to extract protein beyond separating and soon after refolding, Weliky said.

“that study highlights our ability to probe the molecular structure of a indivisible protein in whole cells and to apply forward analytical and biochemical approachs to a problem of general significance in biotechnology,” Weliky said.

angel piece adapted by Medical News Today from original press release.

that research by Weliky and students Jaime CurtisFisk and Ryan M. Spencer was just now featured in Chemical and Engineering News, the membership publication of the American Chemical Society.

Proteins are pivotal biological macromolecules, forming enzymes critical for metabolism, giving cells structural support and comprising key parts of cell signaling, immune response and other life activities. In other words, whatever happens within a living organism, proteins probably assemble it stumble or regulate it.

The heavenly body protein therapeutics trading post totaled $63 billion in 2007, according to square research firm Kalorama lore, and could reach $87 billion by 2010. It gangs to some $39 billion in the United States alone, propelled by recombinant insulin and other drugs. As protein drug use has increased, so has the necessitate for manufacturing capacity and ways to streamline the production of protein.

To access the piece in Chemical and Engineering News, surf the Web at pubs.acs.org/isubscribe/journals/cen/86/i41/html/8641sci1.html. For the original research paper, published in the Journal of the American Chemical Society, go to pubs.acs.org/doi/full/10.1021/ja8039426.

For additional knowledge on Welikys research group, browse chemistry.msu.edu/Faculty/Welikygrp/index.html.

Michigan State University has dйmodй advancing knowledge and transforming lives through innovative teaching, research and outreach for more than 150 years. MSU is known internationally as a major public university with global reach and extraordinary impact. Its 17 stagegranting colleges attract scholars worldwide who are interested in combining drilling with practical problem solving.

Source Mark Fellows
Michigan State University

UCB announced findings from new studies of the oncedaily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extendedrelease tablets comparing tolerability versus levetiracetam immediate release (IR) and reporting on additional dosing schedules. The evidence were among five studies that were presented at the 62nd annual meeting of the American Epilepsy Society (AES) in Seattle.

Keppra XR was approved by the U.S. Food and Drug Administration in September 2008 for use as adjunctive treatment for inhabitants with partialonset seizures who are 16 years of age and older.

“In that new metaanalysis, patients taking Keppra XR experienced fewer nervous conformity side effects than those taking the lookalike dose of twice daily levetiracetam,” said James Zackheim, Medical Director, CNS, UCB. “Keppra XR is the only oncedaily, extendedrelease formulation of levetiracetam, and there is no generic alternative available.”

Summary of Keppra XR goods Presented at 2008 AES Annual Meeting

Safety Profile of Levetiracetam Extended Release Compared to Immediate Release An Indirect Comparison Using a MetaAnalytic Approach

Researchers conducted a metaanalysis of Phase III poop sheet to determine whether Keppra XR is associated with any tolerability advantages versus the double daily dose of levetiracetam IR. According to the metaanalysis, patients taking Keppra XR oncedaily had lower weights of some adverse events versus levetiracetam IR twicedaily.

In terms of overall tolerability, 52.8% of Keppra XR patients reported any adverse event, compared with 79% of patients taking levetiracetam IR.

While adverse events associated with levetiracetam IR were more observed with Keppra XR, patients treated with Keppra XR oncedaily experienced statistically significantly lower weights of adverse events enmeshed to nervous totality disorders (i.e., headache, somnolence and dizziness) versus levetiracetam IR twicedaily.

Keppra XRtreated patients reported numerically lower quotas of psychiatric disorders (i.e., nervousness, anxiety and depression) and nutrition/metabolism disorders.

No other differences in weights of adverse events were statistically significant.

Poster Session 3, Monday, December 8, 800 am 130 pm(Abstract 3.243)

Florent Richy, MPH, PhD, Soutrik Banerjee, MD, PhD, Christophe Gervasoni, MS, Patricia Grossman, PharmD, MBA, Sandra Helmers, MD

UCB Pharma, Inc.; University of Liege, Belgium; Joseph Fourier University, France; Stendhal University, France; Emory University Hospital, USA

original Dose Bioequivalence bounded by Levetiracetam 2 x 750 mg XR Tablets and 3 x 500 mg XR Tablets and Food Effect on 2 x 750 mg XR Tablets in Healthy Subjects

that study demonstrated that an investigational 750 mg tablet strength of Keppra XR is bioequivalent to the approved 500 mg tablet when these are each combined to achieve a 1,500 mg dose. Results Showboat that a rare dose of 2 x 750 mg Keppra XR tablets was bioequivalent to a 3 x 500 mg undivided dose of Keppra XR in healthy adults, and that food intake did not significantly modify Keppra XR 2 x 750 mg disposition.

The median instance to peak plasma concentration was approximately 4 to 5 hours for each dose.

Each dose resulted in a similar halflife (the epoch imperious for half the quantity of a drug in the body to be metabolized or eliminated), apparent total clearance (the rate at which a drug in the body is metabolized or eliminated), and apparent total distribution (the amount of fluid that would be cryed for to dissolve the total amount of drug needed to achieve the carbon counterpart concentration as that construct in the blood).

When the 2 x 750 mg Keppra XR dose was taken with food, the tour to peak concentration was increased by 2 hours relative to fasted intake, while Cmax (the peak concentration of a drug in the body) remained within bioequivalence limits.

For all three Keppra XR dosing schedules (3 x 500 mg, 2 x 750 fasted and 2 x 750 fed), tolerability was privileged and the amounts of treatmentemergent adverse events were similar opposite all associations; in adjoining, adverse events were virtually all mild, and all resolved by the end of the study.

Poster Session 3, Monday, December 8, 800 am 130 pm(Abstract 3.239)

Christian Otoul, Elisabeth Rouits, Ingrid Burton, Evelyne Guenole, Mona Troenaru, Ans Valgaeren, Pierre Boulanger, Maria Laura SargentiniMaier

UCB Pharma SA, BraineLAlleud, Belgium; quarter of Pharmacokinetics, SGS Life information Services, Wavre, Belgium; Therapharm Recherches, Caen, France

Additional Keppra XR measurements Presented at 2008 AES Annual Meeting

Population Pharmacokinetics of Levetiracetam ExtendedRelease 500 mg Tablets

Poster Session 3, Monday, December 8, 800 am 130 pm(Abstract 3.247)

Elisabeth Rouits, M. Lovern, Maria Laura SargentiniMaier and Armel Stockis

UCB Pharma, BraineLAlleud, Belgium

Population DoseResponse Modeling of Levetiracetam Extended and ImmediateRelease Formulations in Adults with PartialOnset Seizures

Poster Session 3, Monday, December 8, 800 am 130 pm(Abstract 3.25)

Rik Schoemaker, Eric Snoeck, Armel Stockis, Christian Otoul, Maria Laura SargentiniMaier

ExprimoNV, Mechelen, Belgium; Pharmacometrics precinct, UCB Pharma SA, BraineLAlleud, Belgium

DoseProportionality of Levetiracetam 500 mg ExtendedRelease Tablets from 1 g to 3 g Once Daily

Poster Session 3, Monday, December 8, 800 am 130 (Abstract 3.263)

Ans Valgaeren, Nathalie Toublanc, Ingrid Burton, Sandrine GeluMantoulet, Mona Troenaru, Christian Otoul, Maria Laura SargentiniMaier, Armel Stockis

UCB Pharma SA, BraineLAlleud, Belgium; territory of Pharmacokinetics, SGS Life discipline Services, Wavre, Belgium; Therapharm Recherches, Caen, France

Keppra XR cannot be substituted with any IR levetiracetam or any other antiepileptic medication at the pharmacy counter outdoors a physicians approval.

serious Safety leak

Keppra XR(TM) extendedrelease tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.

Keppra XR(TM) causes somnolence, dizziness, and behavioral abnormalities. The highest common adverse reactions observed with Keppra XR(TM) in combination with other AEDs were somnolence and irritability.

The adverse reactions that may be seen in patients receiving Keppra XR(TM) are expected to be similar to those seen in patients receiving immediaterelease Keppra(R) tablets.

Keppra(R) immediaterelease tablets cause somnolence and fatigue, coordination difficulties, and behavioral abnormalities (e.g., psychotic symptoms, suicidal ideation, and other abnormalities), as well as hematological abnormalities. In adults experiencing partial onset seizures, the utmost common adverse reactions observed with Keppra(R) in combination with other AEDs were somnolence, asthenia, infection and dizziness.

Keppra XR(TM) should be gradually withdrawn to minimize the probable of increased seizure iteration.

Dosing must be individualized according to the patients renal affair status. In patients with endstage renal disease on dialysis, it is recommended that immediaterelease Keppra(R) be used instead of Keppra XR(TM).

For full prescribing leak, please see KeppraXR.com.

In organization to ensure patient access to that respected medication in the U.S., UCB is initiating a copay support program. For more whole record, contact U.S.

About Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately three million public in the U.S. making it more common than multiple sclerosis and Parkinsons disease combined. It is caused by abnormal, excessive electrical discharges of the nerve cells, or neurons, in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are frequent contrary seizure types and epileptic syndromes. Forty percent of patients taking only one AED linger to struggle seizures, and approximately 30% of patients taking adjunctive therapy maintain to actuality seizures. that highlights the ongoing hurting for for the development of new AEDs. For more learning about epilepsy, explore epilepsyfoundation.org, epilepsy.com, or epilepsyadvocate.com.

About UCB

UCB is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative medicines with a concenter on the fields of central nervous combination and immunology disorders. Employing approximately 12,000 community in more than 40 countries, UCB achieved wages of 3.6 billion euro in 2007. UCB is listed on NYSE Euronext (symbol UCB). Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Georgia. For more break about UCB, see ucbgroup.com.

Forward appearing statement

that press release contains forwardseeing statements based on prevalent plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially distinctive from those that may be implied by such forwardseeing statements selfsupporting in that press release. pressing factors that could outcropping in such differences inject changes in general economic, occupation and competitive conditions, effects of future judicial decisions, changes in regulation, interrelation rate fluctuations and hiring and retention of its employees.

UCB
ucbgroup.com

In recent conflicts, highest notably in Rwanda, women and girls have oldfashioned systematically raped as a channels of war. throughout the Rwandan Genocide of 1994, Hutu leaders ordered their troops to rape Tutsi women as detail of their genocidal fight. United Nations officials estimated that a quarter of a million women were raped and subjected to sexual violence on a massive scale. A new study published in the Journal of Nursing Scholarship explores the lived bit of women who were raped pending the 1994 genocide in Rwanda and finds varied themes exclusive to Rwandan women survivors.

While rape is always a matter of regulating competency relations interpolated the sexes, some differences exist halfway rape in peacetime and wartime. Donatilla Mukamana, Head of Mental tonicity branch, Kigali strength Institute, Rwanda (and Masters height student at the University of KwaZuluNatal, South Africa) and Petra Brysiewicz, Ph.D.,of the University of KwaZuluNatal in South Africa (research supervisor), interviewed seven women who were raped throughout the 1994 Rwandan genocide. The researchers gathered whole scoop that were focused on what happened in the lives of the women and what was of note about their experiences.

The participants reported umpteen themes definitive to the rape pawns who survived the Rwandan genocide.

The women felt violated by perceived inferiors as well as a loss of dignity and respect. To be a woman in Rwandan society implies respect from all divisions of the community. Women were humiliated by public rape, which was carried out in the community by those who were supposed to respect them.

The women felt a loss of identity, loss of hope for the future, and social isolation. In Rwanda, rape and other genderbased violations carry a severe social stigma. Children resulting from rape were seen as being difficult to integrate into Rwandan society and were a source of conflict since they were a constant reminder of what happened over the genocide. The genocide further destroyed support networks seeing participants lost bountiful chapters of their community and class.

Bringing rape survivors wellorganized in an association akin AVEGA (Association of the Widows of the Genocide of April) allows them to recreate a community for themselves. AVEGA helped participants overcome their sense of isolation and gave them medical, psychological, and material corrective.

The results can sustenance nurses to understand war and rape, and thus have needed dossier which can be used to essay assistance to women in these circumstances. “It is hoped that the scholarship regarding the womens actual experiences will make awareness and some understanding of what these women endured,” the authors conclude.

commentary adapted by Medical News Today from original press release.

that study is published in the December 2008 issue of the Journal of Nursing Scholarship.

Petra Brysiewicz, Ph.D., is affiliated with the University of KwaZuluNatal in South Africa.

Reaching fine feather professionals, faculty and students in 90 countries, the Journal of Nursing Scholarship is focused on wholeness of inhabitants overall the globe. It is the conclusive journal of the Honor Society of Nursing, Sigma Theta Tau allembracing, and reflects the honor societys dedication to providing the tools necessary to improve nursing care globally.

WileyBlackwell was formed in February 2007 as a finish of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wileys Scientific, Technical, and Medical biz. stable, the companies have formulated a global publishing employment with deep strength in occasionally major academic and professional field. WileyBlackwell publishes approximately 1,400 scholarly peerreviewed journals and an extensive collection of books with global appeal. For more pipeline on WileyBlackwell, please browse blackwellpublishing.com/ or interscience.wiley.com

Source Amy Molnar
WileyBlackwell

More than 95 % of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU global. They plus experienced lots greater falls in their prostatesole antigen (PSA) levels at 14 and 28 days than men taking leuprolide. Researchers from Canada, the USA, France, Denmark and the Netherlands studied 610 men as item of the Phase Three trial, randomly assigning them to one of three study packs.

“Androgen deprivation hormone therapy is an effective response to prostate cancer, but the drugs that are max widely used cause an initial rise in testosterone the hormone we are shooting for to reduce when the patient first takes them” explains top creator Dr Laurence Klotz from the Division of Urology at the University of Toronto, Canada.

“We tag to sidestep that biochemical surge as it can stimulate the prostate cancer cells and exacerbate a fraction of clinical symptoms, such as spinal cord compression and bone pain. It could conjointly upshot in more rapid growth of microscopic disease that is present in the patient but is too miniature to be detected”.

“Degarelix is a new gonadotrophinreleasing hormone (GnRH) antagonist. It works by binding to, and blocking, the GnRH receptors in the pituitary gland, reducing the amount of LH and FSH hormones that are released. that leads directly to a rapid fall in testosterone.”

Group one (207 patients) received an injection of 240mg of degarelix in month one, followed by a maintenance dose of 80mg now and then month for eleven months and group two (202 patients) received 240mg of degarelix in month one followed by a maintenance dose of 160mg for eleven months.

The third group (201 patients) received a monthly 7.5mg dose of leuprolide, which is a GnRH agonist.

At the start of the trial the study participants had a median testosterone planed of 3.93 ng/mL. The aim was to reduce that to 0.5ng/mL or minus at all monthly measurements from day 28 to day 364.

Eight out of ten study participants completed the trial (504 patients) surrounded by February 2006 and October 2007, with similar dropout and exclusion proportions in all three assemblys.

The key findings were impressive

в?™ Three days after starting their treatment regimes, 96.1% of patients on 240/80mg degarelix and 95.5% of patients on 240/160mg degarelix had achieved a testosterone in line of 0.5ng/mL or out. In contradiction, median testosterone levels in the leuprolide group had increased by 65% by day three, but had reduced by day 28.

в?™ At the end of the study period, 98.3% of the 240/160mg degarelix group and 97.2% of the 240/80mg degarelix group had achieved a testosterone flush of 0.5ng/mL or limited. The figure for the leuprolide group was 96.4%.

� PSA levels fell lots faster in the degarelix pools when measured at 14 and 28 days — by 64 % and 85 % in the degarelix 240/80mg group, 65 % and 83 % in the 240/160mg degarelix group and 18 % and 68 % in the leuprolide group.

The hormonal sideeffects experienced by the three treatment trusts were similar to previously reported effects for androgen deprivation hormone therapy.

“More than 2,000 patients have now taken lump in clinical trials for degarelix and there have outofstyle no signs of immediate or strappedonset systemic allergic reactions, in inverse to other reported trials of other GnRH antagonists” points out Dr Klotz.

“The aim of the study was to view that degarelix was not inferior to leuprolide when it came to maintaining low testosterone levels gone a oneyear treatment period. We have conclusively shown that that is the case”.

“However, we have additionally demonstrated that degarelix which is an antagonist offers an odds, in that it reduces testosterone and PSA levels very quickly. It doesnt cause the initial surge of testosterone seen with agonist drugs analogous leuprolide the other drug featured in that study”.

European Association of Urology
uroweb.org

el Diario de Wall Street el miércoles examinó el uso de aumento de los grupos de derechos del antiaborto del Internet videos y otros medios en línea para ganar a nuevos partidarios y poner en circulación su mensaje. El Diario relata que los productores detrás de CatholicVote.org un grupo de derechos del antiaborto con una presencia en línea fuerte considera su táctica de fijar clips de vídeo en línea cortos “un triunfo estratégico que puede ayudar a la carta un nuevo curso para su movimiento,” que afronta “un clima hostil” bajo la Casa Blanca Controlada por el demócrata y Congreso. El Presidente de CatholicVote.org Brian Burch dijo, “Cuando usted es fuera del poder político, usted comienza a pensar en nuevos modos de hacer cosas.” Un vídeo popular, que ha sido visto casi 1.8 millones de veces en YouTube desde enero, muestra una imagen de ultrasonido de un feto con un título que lee, “el futuro de Este niño es un roto a casa. Él será abandonado por su padre. Su madre sola luchará para levantarle,” antes de que una foto del presidente Obama aparezca. El título entonces lee, “Vida. Imagine el Potencial.” Según el Diario, la nueva estrategia que algunos grupos de derechos del antiaborto llaman “los corazones y mentes” la táctica “depende de la presentación del movimiento de antiaborto en una luz inesperada, el mejor para agarrar y mantener la atención.” El Diario relata que “después de décadas de laboriosamente para construir listas de direcciones un nombre a la vez,” muchos grupos son “conmovidos” para ver un número creciente de espectadores en línea. Algunos defensores de la táctica relatan que ellos han recibido donaciones y cartas que se refieren a videos en línea. Frank Pavone, el director nacional de Sacerdotes para la Vida, dijo que el grupo es “capaz de alcanzar a la gente directamente” por sus videos en línea, que explican procedimientos de aborto por el uso de un modelo plástico de un feto. “Las redes de TV nunca mostrarían este tipo del vídeo, pero ahora que no importa,” dijo Pavone. El padre Thomas Berg, el director del Instituto de Westchester para el Ética y la Persona Humana, dijo que el grupo “se pone más allá de los modos gastados de sostener carteles con cuadros gráficos del aborto,” la adición, “Esto sólo no trabaja.” Susan B. Anthony Lista, un grupo de cabildeo de derechos del antiaborto, también se ha afiliado al movimiento en línea, ofreciendo a 2,000 dólares en premios a activistas que pueden desarrollar videos en línea “que traen nuevo se convierte a la causa,” el Diario hace un informe. los grupos de Derechos del aborto también han dado vuelta a medios en línea, usando mensajería de texto y sitios conectados a una red sociales como el Gorjeo, Facebook, MySpace y YouTube para reunir a partidarios. A favor de Opción NARAL América lanzó un vídeo en línea que enfatiza opciones personales, que ha sido visto aproximadamente 30,000 veces en YouTube, y tanto NARAL como la Federación de Paternidad Planeada de América ha fijado clips en línea de famosos que hablan de la importancia de derechos de aborto. El presidente de NARAL Nancy Keenan dijo, “Todos estos nuevos instrumentos son críticos para activistas simpáticos.” Ella añadió que los derechos del antiaborto en línea recientes videos son demasiado ásperos para persuadir cantidades grandes de las personas porque ellos dejan de dirigirse a las cuestiones que la mayor parte de personas dicen son importantes, como la prevención de embarazos involuntarios o conservación de la salud femenina. Según el Diario, NARAL y videos de la Paternidad Planeada han recibido mucho menos golpes que las campañas de los grupos de derechos del antiaborto, “y algunos analistas de mucho tiempo de la política de aborto dicen que la campaña en línea del derecho parece tener un impacto.” Alesha el Doan, un científico político en la Universidad de Kansas y un partidario de derechos del aborto, dijo, “Seguramente, hay una predicación al efecto de coro, pero no pienso que usted puede rebajar el efecto en la sociedad con el tiempo.” Ella dijo que los grupos de derechos del antiaborto han sido capaces de humanizar el feto en las mentes de algunas personas por imágenes de ultrasonido circulantes en línea, adición, “he visto un cambio marcado de como la gente habla del aborto,” la gente sobre todo joven (Simon, Diario de Wall Street, 4/1).

Reimprimido con permiso amable de nationalpartnership.org. Usted puede ver el Informe de Política de Salud Femenino Diario entero, buscar los archivos, o contratarse para la entrega de correo electrónico aquí. El Informe de Política de Salud Femenino Diario es un servicio libre de la Sociedad Nacional para Mujeres y Familias, publicadas por la Compañía de Consejo Consultivo.

*copy; 2009 la Compañía de Consejo Consultivo. Reservados todos los derechos.